Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Development of evaluation of B/F benzothiazole analogues for boron neutron capture therapy

  • Ji-ung Yang (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Soyeon Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Kyo Chul Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Yong Jin Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Jung Young Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Ji-Ae Park (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS))
  • Received : 2022.06.03
  • Accepted : 2022.06.23
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Boron neutron capture therapy is a precision treatment technology that selectively destroys only tumor cells by irradiating thermal neutrons after accumulating boron drugs in tumor cells. Brain tumor is difficult to diagnose and treat due to the low permeability and targeting of drugs caused by the blood-brain-barrier. Crossing the BBB is essential for drug delivery to the brain. In this study, we designed and synthesized a novel compound incorporating benzothiazole to develop a boron drug with high BBB permeability and selectivity for brain tumor cells. In addition, their potential as a BNCT drugs was evaluated.

Keywords

Acknowledgement

이 논문은 한국연구재단 중견연구자지원산업(2020R1A2C200790611)과 과학기술정보통신부 한국원자력의학원 연구운영비지원사업(50532-2022)의 지원에 의하여 이루어 이루어졌 이루어졌으며 이해관계는 없음을 밝힙니다.

References

  1. Barth RF. A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 2003;62(1-2):1-5.
  2. Sauerwein WA. Principles and roots of neutron capture therapy. In: Sauerwein WA, Wittig A, Moss R, Nakagawa Y, editors. Neutron Capture Therapy. New York : Springer-Verlag; 2012. p. 1-3.
  3. Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun 2018;38(1):35.
  4. Barth RF, Coderre JA, Vicente MGH, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin cancer Res 2005;11(11):3987-4002. https://doi.org/10.1158/1078-0432.CCR-05-0035
  5. Barth RF, Soloway AH, Fairchild RG, Brugger RM. Boron neutron capture therapy for cancer. Realities and prospects. Cancer 1992;70(12): 2995-3007. https://doi.org/10.1002/1097-0142(19921215)70:12<2995::AID-CNCR2820701243>3.0.CO;2-#
  6. Soloway AH, Tjarks W, Bamum BA, Rong FG, Barth RF, Codogni IM, Wilson JG. The chemistry of neutron capture therapy. Chem Rev 1998;98(4): 1515-62. https://doi.org/10.1021/cr941195u
  7. Ishiwata K. 4-Borono-2-18F-fluoro-l-phenylalanine PET for boron neutron capture therapy-oriented diagnosis: overview of a quarter century of research. Ann Nucl Med 2019;33(4):223-36. https://doi.org/10.1007/s12149-019-01347-8
  8. Evangelista L, Jori G, Martini D, Sotti G. Boron neutron capture therapy and 18F-labelled borophenylalanine positron emission tomography: a critical and clinical overview of the literature. Appl Radiat Isot 2013;74:91-101. https://doi.org/10.1016/j.apradiso.2013.01.001
  9. Sauerwein WA, Bet PM, Wittig A. Drugs for BNCT: BSH and BPA. In: Sauerwein WA, Wittig A, Moss R, Nakagawa Y, editors. Neutron Capture Therapy. Berlin : Springer-Verlag; 2012. p. 117-60.
  10. Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A 1991 ;42(4):325-8. https://doi.org/10.1016/0883-2889(91)90133-L
  11. 11 He J, Yan H, Du Y, Ji Y, Cai F, Fan W. Nucleophilic radiosynthesis of boron neutron capture therapy-oriented PET probe [18F]FBPA using aryldiboron precursors. Chem Commun 2021;57(71):8953-6. https://doi.org/10.1039/D1CC03369G
  12. Bradshaw TD, Westwell AD. The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem 2004;11(8):1009-21. https://doi.org/10.2174/0929867043455530
  13. Perepechaeva ML, Grishanova AY The role of aryl hydrocarbon receptor (AHR) in brain tumors. Int J Mol Sci 2020;21(8):2863.
  14. Di L, Kems EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003;38(3):223-32. https://doi.org/10.1016/S0223-5234(03)00012-6
  15. Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur J Pharm Biopharm 2010;74(3):495-502. https://doi.org/10.1016/j.ejpb.2010.01.003
  16. Zamenhof RG, Murray BW, Brownell GL, Wellum GR, Tolpin EL Boron neutron capture therapy for the treatment of cerebral gliomas. I: Theoretical evaluation of the efficacy of various neutron beams. Medical Physics; 1975;2(2):47-60. https://doi.org/10.1118/1.594168
  17. Tolpin El, Wellum GR, Dohan FCJ, Komblith PL, Zamenhof RG. Boron neutron capture therapy of cerebral gliomas. II. Utilization of the blood-brain barrier and tumor-specific antigens for the selective concentration of boron in gliomas. Oncology 1975;32(5-6):223-46. https://doi.org/10.1159/000225073
  18. Pathan SA, Iqbal Z, Zaidi SM, Talegaonkar S, Vohra D, Jain GK, Azeem A, Jain N, Lalani JR, Khar RK, Ahmad FJ. CNS Drug Delivery Systems: Novel Approaches. Recent Pat Drug Deliv Formul 2009;3(1):71-89. https://doi.org/10.2174/187221109787158355
  19. Fukuda H, Hiratsuka J. Pharmacokinetics of 10B-p-boronophenylalanine (BPA) in the blood and tumors in human patients: A critical review with special reference to tumor-to-blood (T/B) ratios using resected tumor samples. Appl Radiat Isot 2020; 166:109308.
  20. Hu K, Yang Z, Zhang L, Xie L, Wang L, Xu H, Josephson L, Liang SH, Zhang M-R. Boron agents for neutron capture therapy. Coord Chem Rev 2020;405:213139.
  21. Kim S, Yang J, Lee KC, Kim JY Lee YJ, Park J. Preliminary research on the development of boron neutron capture therapy drugs. J Radiopharm Mol Probes 2021;7(1):3-10.
  22. Watanabe T, Hattori Y, Ohta Y, Ishimura M, Nakagawa Y, Sanada Y, Tanaka H, Fukutani S, Masunaga SI, Hiraoka M, Ono K, Suzuki M, Kirihata M. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: A validation study for the theranostic approach using [18F]-L-FBPA. positron emission tomography in boron neutron capture therapy. BMC Cancer 2016;16(1):1-10. https://doi.org/10.1186/s12885-015-2026-y
  23. Capuani S, Porcari P, Fasano F, Campanella R, Maraviglia B. 10B-editing 1H-detection and 19F MRI strategies to optimize boron neutron capture therapy. Magn Resort Imaging 2008;26(7):987-93. https://doi.org/10.1016/j.mri.2008.01.040
  24. Bradshaw KM, Schweizer MP, Glover GH, Hadley JR, Tippets R, Tang PP, Davis WL, Heilbrun MP, Johnson S, Ghanem T. BSH distributions in the canine head and a human patient using 11B MRI. Magn Resort Med 1995;34(1):48-56. https://doi.org/10.1002/mrm.1910340109
  25. Bendel P, Koudinova N, Salomon Y. In vivo imaging of the neutron capture therapy agent BSH in mice using 10B MRI. Magn Reson Med 2001;46(1):13-7. https://doi.org/10.1002/mrm.1154